SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 224 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,140,605 | -4.9% | 1,093,097 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $31,687,638 | -15.7% | 1,054,146 | +1.6% | 0.00% | -20.0% |
| Q1 2023 | $37,588,384 | +104594.3% | 1,037,493 | +3.1% | 0.01% | 0.0% |
| Q4 2022 | $35,903 | -99.9% | 1,006,547 | +6.1% | 0.01% | 0.0% |
| Q3 2022 | $32,120,000 | +18.3% | 948,910 | +1.0% | 0.01% | +25.0% |
| Q2 2022 | $27,159,000 | -9.6% | 939,141 | +1.0% | 0.00% | 0.0% |
| Q1 2022 | $30,057,000 | +7.2% | 930,007 | -3.3% | 0.00% | +33.3% |
| Q4 2021 | $28,043,000 | +10.8% | 961,708 | +1.3% | 0.00% | 0.0% |
| Q3 2021 | $25,310,000 | -9.2% | 949,013 | +4.8% | 0.00% | -25.0% |
| Q2 2021 | $27,886,000 | +22.5% | 905,691 | +4.1% | 0.00% | +33.3% |
| Q1 2021 | $22,766,000 | +13.8% | 869,624 | +9.3% | 0.00% | 0.0% |
| Q4 2020 | $20,013,000 | +25.9% | 795,431 | +4.2% | 0.00% | 0.0% |
| Q3 2020 | $15,902,000 | -13.4% | 763,058 | -1.3% | 0.00% | -25.0% |
| Q2 2020 | $18,356,000 | +34.6% | 772,907 | +1.9% | 0.00% | 0.0% |
| Q1 2020 | $13,642,000 | -59.8% | 758,343 | -47.0% | 0.00% | 0.0% |
| Q4 2019 | $33,936,000 | +77.7% | 1,430,768 | +105.8% | 0.00% | 0.0% |
| Q3 2019 | $19,100,000 | -14.6% | 695,085 | +2.9% | 0.00% | -20.0% |
| Q2 2019 | $22,361,000 | +0.5% | 675,766 | +6.4% | 0.01% | -16.7% |
| Q1 2019 | $22,244,000 | -43.1% | 634,830 | -46.0% | 0.01% | 0.0% |
| Q4 2018 | $39,082,000 | +42.7% | 1,176,518 | +116.3% | 0.01% | -25.0% |
| Q3 2018 | $27,389,000 | -13.1% | 543,991 | +3.3% | 0.01% | -20.0% |
| Q2 2018 | $31,518,000 | +37.8% | 526,625 | +5.4% | 0.01% | +42.9% |
| Q1 2018 | $22,876,000 | +23.5% | 499,489 | +7.5% | 0.01% | +16.7% |
| Q4 2017 | $18,519,000 | +3.1% | 464,740 | +3.4% | 0.01% | -14.3% |
| Q3 2017 | $17,970,000 | -8.2% | 449,251 | -1.1% | 0.01% | -12.5% |
| Q2 2017 | $19,584,000 | +39.7% | 454,409 | +1.5% | 0.01% | +33.3% |
| Q1 2017 | $14,015,000 | +46.7% | 447,824 | +18.3% | 0.01% | +50.0% |
| Q4 2016 | $9,554,000 | +12.2% | 378,429 | +9.9% | 0.00% | 0.0% |
| Q3 2016 | $8,518,000 | +51.5% | 344,475 | +24.8% | 0.00% | +33.3% |
| Q2 2016 | $5,623,000 | +56.2% | 276,082 | +16.9% | 0.00% | +50.0% |
| Q1 2016 | $3,601,000 | -6.3% | 236,187 | -17.4% | 0.00% | 0.0% |
| Q4 2015 | $3,843,000 | -3.4% | 285,959 | +0.9% | 0.00% | 0.0% |
| Q3 2015 | $3,977,000 | -1.9% | 283,541 | +18.8% | 0.00% | 0.0% |
| Q2 2015 | $4,052,000 | +117.4% | 238,689 | +54.8% | 0.00% | +100.0% |
| Q1 2015 | $1,864,000 | +52.8% | 154,205 | +4.9% | 0.00% | 0.0% |
| Q4 2014 | $1,220,000 | -4.2% | 147,020 | +0.4% | 0.00% | 0.0% |
| Q3 2014 | $1,273,000 | -17.4% | 146,498 | +4.1% | 0.00% | 0.0% |
| Q2 2014 | $1,541,000 | +101.7% | 140,739 | +64.5% | 0.00% | 0.0% |
| Q1 2014 | $764,000 | +27.1% | 85,534 | +7.3% | 0.00% | – |
| Q4 2013 | $601,000 | +35.4% | 79,715 | +31.7% | 0.00% | – |
| Q3 2013 | $444,000 | +18.1% | 60,513 | +3.5% | 0.00% | – |
| Q2 2013 | $376,000 | – | 58,477 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |